Publications by authors named "Anne-Flore Plane"
Article Synopsis
- The study investigates whether ibrutinib-related atrial fibrillation (IRAF) is linked to the dosage of ibrutinib, and if IRAF cases should lead to dosage adjustments or discontinuation of the drug.
- Researchers analyzed data from the World Health Organization's VigiBase® pharmacovigilance database, focusing on 1,162 IRAF cases and various dosing regimens of ibrutinib (ranging from 140 mg/day to over 560 mg/day).
- Results indicated that there was no significant association between the reported IRAF cases and the dosage of ibrutinib (p=0.09), suggesting IRAF is not a dose-dependent adverse drug reaction.
Article Synopsis
- The study aimed to evaluate the incidence of atrial fibrillation (AF) linked to 19 anticancer drugs used alone in clinical trials, focusing on how common AF is among cancer patients receiving these treatments.
- Researchers analyzed 191 clinical trials involving 16 anticancer drugs and found that AF rates varied from 0.26 to 4.92 cases per 100 person-years, with the highest rates associated with ibrutinib, clofarabine, and ponatinib.
- The findings highlight that AF is a significant concern in patients undergoing treatment with these drugs, suggesting the need for better monitoring procedures in clinical trials for drugs known to cause higher AF rates.
Article Synopsis
- The study aimed to investigate the cardiovascular immune-related adverse events (irAEs) linked to immune checkpoint inhibitors (ICIs) in cancer patients, as the risks and incidence of these events were not well understood.
- Researchers reviewed randomized clinical trials (RCTs) to analyze data on various cardiovascular adverse events (CVAEs), finding that ICI exposure significantly increased the risk of six specific CV irAEs, including myocarditis and dyslipidemia.
- The incidence of these cardiovascular events varied between 3.2 to 19.3 per 1000 patients, emphasizing the need for awareness among healthcare providers regarding these potential risks when using ICIs.
Article Synopsis
- LVAD implantation can be a viable treatment option for elderly patients (70+) with heart failure who aren't suitable for heart transplants.
- An observational study analyzed 652 patients from 2006 to 2016, with 74 (11.3%) being elderly, showing similar hospitalization patterns and complication rates between elderly and younger patients.
- The findings indicate that elderly patients receiving LVADs have comparable mid-term survival rates to younger patients, supporting the use of LVADs in this age group.
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Arch Cardiovasc Dis
September 2020
Background: The risk of cardiovascular adverse events from rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is not fully characterized.
Aim: To evaluate the cardiovascular adverse events risks related to BRAF and/or MEK inhibitors in randomized placebo-controlled clinical trials and in the real-life setting.
Methods: We used two approaches.
Aims: The explosion of novel anticancer therapies has meant emergence of cardiotoxicity signals including atrial fibrillation (AF). Reliable data concerning the liability of anticancer drugs in inducing AF are scarce. Using the World Health Organization individual case safety report database, VigiBase®, we aimed to determine the association between anticancer drugs and AF.
View Article and Find Full Text PDFImportance: Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after an immune-related adverse event (irAE).
Objective: To identify the recurrence rate of the same irAE that prompted discontinuation of ICI therapy after an ICI rechallenge in patients with cancer and to identify the clinical features associated with such recurrences.
Design, Setting, And Participants: This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from the World Health Organization database VigiBase, which contains case reports from more than 130 countries.
Background: Immune checkpoint inhibitor (ICI)-associated early cardiac adverse events (CAEs), mostly acute and fulminant myocarditis, have been well characterized and mainly occur during the first 90 days after ICI therapy initiation. ICI-associated late CAEs (occurring after the first 90 days of treatment) have not yet been described.
Methods: First, we compared characteristics of a cohort involving early (defined as a CAE time to onset (TTO) of <90 days after ICI therapy initiation) and late (defined as a CAE TTO of ≥90 days after ICI therapy initiation) ICI-associated CAE consecutive cases who were referred to three French cardio-oncology units.
This report describes the case of a 48-year-old man whose electrocardiogram after cardiopulmonary resuscitation showed up-sloping ST-segment depression at the J point in precordial leads combined with tall symmetrical T waves. This electrocardiographic pattern corresponded to de Winter syndrome and is related to proximal left anterior descending coronary artery occlusion. ().
View Article and Find Full Text PDFWhether oral anticoagulants, vitamin K antagonists (VKAs), and nonvitamin K oral anticoagulant (NOACs) frequently prescribed to atrial fibrillation (AF) patients, do themselves have a pro- or anti-arrhythmic effect have never been addressed. Transmembrane action potentials were recorded in an acute rabbit model of superfused pulmonary veins (PVs) sleeves preparations using standard microelectrode technique. Fluindione 10 μm (n = 6) increased the AP (action potential) duration (APD), induced a significantly V depression (from 95 ± 14 to 53 ± 5 V/s, P < 0.
View Article and Find Full Text PDFObjective: Postoperative atrial fibrillation (POAF) is associated with poor outcomes after coronary artery bypass graft (CABG) surgery. We aimed to assess the additional value of preoperative plasma aldosterone levels, a biomarker promoting proarrhythmic and profibrotic pathways, for predicting POAF after CABG.
Methods: We conducted a prospective cohort study involving consecutive patients with left ventricular ejection fraction (LVEF) more than 50% requiring elective CABG in our university hospital.